Kelly Jared
Chief Executive Officer
Kelly Jared has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Mar 13, 2026.
On the most recent filing, Kelly Jared is listed as Chief Executive Officer at ONCOLYTICS BIOTECH INC. Inside the rolling window, Kelly Jared reported 3 open-market purchases totaling $34K in ONCY and no open-market sales. The largest disclosed transaction in the window is a purchase of 29,500 ONCY shares on Feb 12, 2026, worth $25K.
Companies traded
Other insiders at ONCY
Insider Buying
$34K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Kelly Jared made?
Kelly Jared has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company since 2026.
Which companies does Kelly Jared trade?
Kelly Jared has filed SEC Form 4 disclosures for 1 company, including ONCY.
When was Kelly Jared's most recent SEC Form 4 filing?
Kelly Jared's most recent SEC Form 4 filing on Tracefour is dated Mar 13, 2026.
What is Kelly Jared's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Kelly Jared is listed as Chief Executive Officer.
What is Kelly Jared's total buy and sell value in the current window?
Inside the rolling retention window, Kelly Jared bought $34K and sold $0 based on SEC Form 4 filings.
What was Kelly Jared's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 29,500 ONCY shares on 2026-02-12, worth $25K, per SEC Form 4 filings.